When was Servier Pharmaceuticals founded?

Servier Pharmaceuticals was founded in 1954.

Where is Servier Pharmaceuticals located?

Servier Pharmaceuticals is headquartered in Boston, United States. It is registered at Boston, Massachusetts.

How many employees does Servier Pharmaceuticals have?

As of May 31, 2026, the latest employee count at Servier Pharmaceuticals is 954.

Is Servier Pharmaceuticals a funded company?

Servier Pharmaceuticals is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Servier Pharmaceuticals rank among its competitors?

Servier Pharmaceuticals ranks 29th amongst 96 active competitors, of which 32 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was CERo Therapeutics, which secured $750K in May, 2026.

Who are the top competitors of Servier Pharmaceuticals?

Servier Pharmaceuticals' top competitors include Ossium Health, Rigel and Ajax. Among them, CERo Therapeutics secured the most recent funding round in May, 2026.

Servier Pharmaceuticals - 2026 Company Profile & Competitors

Company Details

Servier Pharmaceuticals provide therapeutics for cancer. The company's lead candidate, Oncaspar, is a cancer medicine used in adults and children to treat acute lymphoblastic leukemia (ALL), a cancer of white blood cells called lymphoblasts. The candidate contains the active substance pegaspargase, which is a modified enzyme used as an antineoplastic agent.

Website: servier.us
Social
Phone Number: +1 **********
Registered Address: Boston, Massachusetts

Key Metrics

Founded Year

1954

Location

Boston, United States

Stage

Unfunded

Ranked

29^th among 96 active competitors

Employee Count

954 as on May 31, 2026

Similar Companies

Ossium Health & 98 more

View Servier Pharmaceuticals' full profile

Servier Pharmaceuticals is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Servier Pharmaceuticals Llc CIN: 371897970 , United States, Active	Dec 26, 999	-	495 (As on Dec 31, 2024)	-

Servier Pharmaceuticals has not raised any funding rounds yet.

Servier Pharmaceuticals' employee count trend

Servier Pharmaceuticals has 954 employees as of May 26. Here is Servier Pharmaceuticals's employee count trend over the years:

Employee count trend for Servier Pharmaceuticals

Uncover Servier Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Servier Pharmaceuticals include Ossium Health, Rigel and Ajax. Here is the list of Top 10 competitors of Servier Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Ossium Health 2016, San Francisco (United States), Series C	Developer of cell therapy products for blood cancers, tissue damage healing & radiation poisoning	$125M	Vivo Capital, CPMG & 12 others	65/100
2nd	Rigel 1996, San Francisco (United States), Public	Developer of drugs for hematologic disorders, cancer, and rare immune disease	-	MPM Capital, New Enterprise Associates & 6 others	64/100
3rd	Ajax 2019, Cambridge (United States), Acquired	Developer of targeted therapies for the treatment of hematologic malignancies	$135M	EcoR1, Goldman Sachs Asset Management & 8 others	64/100
4th	Orca Bio 2016, Menlo Park (United States), Series F	Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders	$300M	Lightspeed Venture Partners, Mubadala & 11 others	63/100
5th	MaaT Pharma 2014, Lyon (France), Public	Developer of microbiome therapy for the treatment of intestinal dysbiosis diseases	$42.3M	Bpifrance, Symbiosis & 11 others	61/100
6th	Adicet Bio 2014, Menlo Park (United States), Public	Developer of immune cell therapeutic solutions for the treatment of cancer	$51M	Consensus Business Group, Orbimed & 18 others	61/100
7th	CERo Therapeutics 2016, San Francisco (United States), Public	Developer of platforms for cellular immunotherapy	$54.8M	SRx Health, Arch Venture Partners & 1 others	58/100
8th	StemlineTherapeutics 2003, New York City (United States), Acquired	Oncology therapeutics innovator focused on transforming cancer patient lives	$15.1M	Avoro Capital, Great Point Partners & 1 others	58/100
9th	Charm Therapeutics 2021, London (United Kingdom), Series B	Developer of menin inhibitors designed for acute myeloid leukemia treatment	$150M	New Enterprise Associates, F-Prime Capital ... & 11 others	58/100
10th	Curocell 2016, Yuseong District (South Korea), Series D	Developer of immune cell therapies	$82.4M	QUAD, DS & 21 others	56/100
29th	Servier Pharmaceuticals 1954, Boston (United States), Unfunded	Provider of therapeutics for cancer	-	-	46/100